REVERSING AUTOIMMUNITY THROUGH CELL THERAPY
REACT-01
What is the goal of the study?
This phase 1, open-label, non-randomized study will enroll pediatric and young adult research participants with treatment-refractory Systemic Lupus Erythematosus (SLE), to examine the safety, feasibility, and efficacy of administering T cell products derived from peripheral blood mononuclear cells (PBMC) that have been genetically modified using self-inactivating (SIN) lentiviral vector to express CD19 -specific chimeric antigen receptor (CAR) with the selection suicide marker EGFRt. The primary objectives of the study will be to determine the feasibility of manufacturing the cell product, the safety of the T cell product infusion, and to describe the full toxicity profile of anti-CD19 CAR T cells in SLE.
Who can participate in the study?
Please contact the study team listed below to learn more.